As the CEO and co-founder of NetraMark Corp, I am very excited about the novel explainable machine learning paradigm that we have created called NetraAI. This technology puts us at the forefront of understanding patient subpopulations.

NetraMark utilizes next generation ML technologies to extract unknown insights about patient populations with two goals in mind:  

 1) To optimize clinical trials via these insights   

2) To create a new taxonomy of disease in order to better understand how to repurpose/resurrect drugs and create new therapeutics.

Psychiatric illnesses, oncology, dementia + other neurological diseases, and age related diseases, are highly heterogeneous and a new approach will be required in order to discover the next generation of therapeutics. Our technology was designed to unpack these unknown patient subpopulations and provide insights into how to target them. The way our technology does is by utilizing a unique learning paradigm different from ensemble trees and deep neural networks, that can learn what is not known, and explain itself.